Disparate outcomes in Hispanic patients with metabolic dysfunction-associated steatotic liver disease/steatohepatitis and type 2 diabetes: Large cohort study

Table 2 Risk analyses of primary outcomes between Hispanic/Latino and non-Hispanic/Latino metabolic dysfunction-associated steatohepatitis patients in United States and University of Texas Medical Branch cohorts

Outcomes	Risk ratio	95%CI	P value
All-cause mortality (R99.0)
United States cohort	0.924	0.868-0.983	0.013
UTMB cohort	1.000	0.749-1.335	1.000
HCC (C22.0)
United States cohort	2.183	1.964-2.426	< 0.001
UTMB cohort	4.010	2.008-8.007	< 0.001
T2DM (E11)
United States cohort	1.169	1.139-1.200	< 0.001
UTMB cohort	1.066	1.027-1.106	0.001
Fibrosis/cirrhosis of the liver (K74)
United States cohort	1.117	1.084-1.151	< 0.001
UTMB cohort	1.388	1.207-1.596	< 0.001

All results, including rates of hepatocellular carcinoma, type 2 diabetes mellitus, fibrosis/cirrhosis, and all-cause mortality were significant with the exception of all-cause mortality in the University of Texas Medical Branch cohort alone. UTMB: University of Texas Medical Branch; HCC: Hepatocellular carcinoma; T2DM: Type 2 diabetes mellitus.